SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
 
   Summit Therapeutics plc 
 
   ("Summit", or the "Company") 
 
   SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE 
 
   Oxford, UK, 9 January 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: 
SUMM), the drug discovery and development company advancing therapies 
for rare diseases and infectious diseases, announces that it will 
present at the Biotech Showcase(TM), taking place 8-10 January in San 
Francisco, CA, US. The presentation will take place today, 9 January, at 
4:00pm PST. 
 
   A live audio webcast of the presentation will be available through the 
Investors section on the Company's website, www.summitplc.com. A replay 
of the webcast will be available from the same location soon after the 
live presentation. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease, Duchenne 
muscular dystrophy, and the infectious disease, Clostridium difficile 
infection. Further information is available at www.summitplc.com and 
Summit can be followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)        Tel:          44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery (US office)                    +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                     Tel:         +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                     Tel:         +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer 
 
Panmure Gordon (Joint Broker)                 Tel:         +44 (0)20 7886 2500 
Freddy Crossley / Duncan Monteith, 
Corporate Finance 
Tom Salvesen, Corporate Broking 
 
MacDougall Biomedical Communications (US)     Tel:             +1 781 235 3060 
Karen Sharma                                             ksharma@macbiocom.com 
 
Consilium Strategic Communications (UK)       Tel:         +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart /                    summit@consilium-comms.com 
Jessica Hodgson / Philippa Gardner 
 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

January 09, 2018 07:00 ET (12:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024